BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 20, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

EVT 302: Phase II data

Data from a double-blind, German Phase II trial (EVT 302/3009) in 414 smokers showed that once-daily EVT 302 missed the primary endpoint of a significant improvement in 4-week continuous quit rate for the last 4 weeks of the 8-week treatment period vs. placebo....

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >